Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
ATRA
ATRA
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ATRA News
Atara Biotherapeutics Faces Securities Fraud Investigation
2d ago
PRnewswire
Pomerantz LLP Investigates Securities Fraud Claims Against Atara Biotherapeutics
Feb 03 2026
Globenewswire
Atara Biotherapeutics Faces Securities Fraud Investigation
Jan 29 2026
PRnewswire
Atara Biotherapeutics Under Investigation After 57% Stock Drop Following FDA Response
Jan 22 2026
PRnewswire
Atara Biotherapeutics Under Investigation After 57% Stock Drop Following FDA Response
Jan 20 2026
Globenewswire
Atara Biotherapeutics' Ebvallo Receives EU Approval, Faces Second FDA Rejection
Jan 14 2026
Benzinga
Atara Biotherapeutics' EBVALLO BLA Rejected by FDA, Stock Plummets 57%
Jan 13 2026
NASDAQ.COM
Atara Biotherapeutics (ATRA) Shares Plunge 53% After FDA Issues Complete Response Letter for Tabelecleucel
Jan 12 2026
seekingalpha
Atara Biotherapeutics Faces Second FDA Rejection for EBVALLO, Shares Plunge 53%
Jan 12 2026
stocktwits
U.S. Stocks Mixed; Day One Biopharmaceuticals Shares Surge 20%
Jan 12 2026
Benzinga
Atara Biotherapeutics Faces FDA Rejection, Stock Plummets 52.74%
Jan 12 2026
Benzinga
Dow Jones Falls Over 250 Points as Financial Stocks Decline
Jan 12 2026
Benzinga
FDA Approves First CAR T-Cell Therapy and Digital Health Pilot
Dec 30 2025
NASDAQ.COM
Pacira (PCRX) Exceeds Q3 Earnings Projections
Nov 07 2025
NASDAQ.COM
Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)
Nov 03 2025
PRnewswire
4 Biotechnology Stocks Leading the Way with Strong Momentum and Technical Performance
Sep 29 2025
Benzinga
Show More News
